Sino Biopharmaceutical (HKSE:01177) Ending Cash Position : HK$8,209 Mil (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Sino Biopharmaceutical Ending Cash Position?

Sino Biopharmaceutical's Ending Cash Position for the quarter that ended in Dec. 2023 was HK$8,209 Mil.

Sino Biopharmaceutical's quarterly Ending Cash Position declined from Dec. 2022 (HK$9,665 Mil) to Jun. 2023 (HK$3,603 Mil) but then increased from Jun. 2023 (HK$3,603 Mil) to Dec. 2023 (HK$8,209 Mil).

Sino Biopharmaceutical's annual Ending Cash Position declined from Dec. 2021 (HK$11,754 Mil) to Dec. 2022 (HK$9,665 Mil) and declined from Dec. 2022 (HK$9,665 Mil) to Dec. 2023 (HK$8,209 Mil).

Sino Biopharmaceutical Ending Cash Position Historical Data

The historical data trend for Sino Biopharmaceutical's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Ending Cash Position Chart

Sino Biopharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

11,829.89

12,594.27

11,754.32

9,664.95

8,208.92

Sino Biopharmaceutical Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Ending Cash Position	Get a 7-Day Free Trial															1,923.90	7,109.90	9,664.95	3,602.87	8,208.92

Sino Biopharmaceutical Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Sino Biopharmaceutical's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	9466.443	+	-1257.525
	=	8,209

Sino Biopharmaceutical's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	3602.87	+	4606.048
	=	8,209

Sino Biopharmaceutical Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical (HKSE:01177) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (HKSE:01177) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

SBHMY:USA SBMFF:USA SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (HKSE:01177) Headlines

No Headlines